CatalystMarker
← board

ZIVO

distress 4/10 · elevated risk
$4.000%today-79% from 52w high
zivobioscience.com7 employeesTroy, MIBiotechnology
Revenue
pre-revenue
Liquidity
$0M
Runway
0.0 yrs
Shares 1y
+2%

Price & events

-52.2% over 6M
$1.17$5.96$10.75Jan 26Apr 26Jul 2637kdilution: EFFECT shelf_effective (2026-04-01)catalyst: regulatory_submission (2026-03-30) — click to open
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
-7.8%
1W
+8.4%
1M
+233.3%
3M
-52.2%
6M
-69.8%
1Y
-52.7%
2Y
-81.7%
5Y
-94.4%
All

Overview

Market Cap
$15.55M
Volume
0
52 Week Range
$1.17 – $19.01
Total Shares
3.89M
Float Shares
1.47M
Short %
2.61%
% Held by Insiders
48.02%
% Held by Institutions
0.11%
Beta
0.11

Pipeline · 0 trials · 0 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
No pipeline trials tracked.

Catalyst news & presentations · 1

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: 3,888,595 · 0 offerings/1y · 0 PIPEs
  • 2026-04-01EFFECTshelf_effective
  • 2025-07-148-Kmaterial_agreement
  • 2025-01-278-Kprivate_placement
  • 2025-01-158-Kmaterial_agreement
  • 2024-11-158-Kmaterial_agreement
  • 2024-10-188-Kprivate_placement
  • 2024-10-01SC 13D/Astrategic_stake
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

no consensus
  • no recent rating changes

Competitors

  • none identified

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.